Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2010

View Archived Issues

Preclinical and clinical data presented on antibiotic CB-183315

Lundbeck describes new neuropeptide Y5 receptor antagonists

U.S. scientists claim new MAPK 8 inhibitors

MorphoSys and Proteros Biostructures receive grant to develop new technology platform

Biotie regains rights to phosphodiesterase 10 inhibitors for CNS disorders

Phase I data reported on Zealand Pharma's ZP-1848 in Crohn's disease

Phase I trials assess safety, tolerability and pharmacokinetics of ASM-024

DCVax-L is well tolerated combined with other anticancer agents in ovarian cancer

PEGylated opioid analgesic NKTR-181 demonstrates slowed entry into CNS

Tekmira receives grant to develop RNAi agents against Ebola and Marburg virus infections

Genmab reports feedback from U.S. and E.U. authorities on zalutumumab

EC grants orphan drug status for pralatrexate in Hodgkin's lymphoma

Labopharm and Paladin Labs enter agreements on pain medications

Amgen reviews TREAT data and proposes updates to ESA labeling

New protein kinase inhibitors identified by sanofi-aventis

FDA approves ISTA's sNDA for bromfenac ophthalmic solution Bromday

Inhibitex completes enrollment in phase II FV-100 trial in shingles

New inhibitors of dual specificity protein kinase TTK claimed

Glenmark Pharmaceuticals patents new TRPA1 modulators

FDA approves Botox as treatment for chronic migraine

Celgene acquires Abraxis BioScience

EMA grants orphan drug status for forodesine in chronic lymphocytic leukemia

Phosphagenics to advance TPM oxycodone patch

New selective serine/threonine-protein kinase 6 inhibitors discovered

Levetiracetam does not improve cerebellar symptoms of multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...